Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tulmimetostat |
| Synonyms | |
| Therapy Description |
Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which may lead to decreased tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 3094)). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tulmimetostat | CPI0209|CPI-0209|CPI 0209 | EZH1 inhibitor 5 EZH2 inhibitor 20 | Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which may lead to decreased tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 3094)). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A P549fs ARID1A N756fs | ovarian clear cell carcinoma | sensitive | Tulmimetostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tulmimetostat inhibited viability of an ovarian clear cell carcinoma cell line harboring ARID1A N756fs and P549fs in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38833522). | 38833522 |
| ARID1A inact mut | endometrial cancer | sensitive | Tulmimetostat | Preclinical - Pdx | Actionable | In a preclinical study, Tulmimetostat inhibited tumor growth in endometrial cancer patient-derived xenograft (PDX) models harboring loss of function mutations in ARID1A (PMID: 38833522). | 38833522 |
| ARID1A G1450fs | urinary bladder cancer | sensitive | Tulmimetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522). | 38833522 |
| ARID1A S2256* | urinary bladder cancer | sensitive | Tulmimetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S2256* in culture (PMID: 38833522). | 38833522 |
| ARID1A S552* | urinary bladder cancer | sensitive | Tulmimetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S552* in culture (PMID: 38833522). | 38833522 |
| ARID1A inact mut | urinary bladder cancer | sensitive | Tulmimetostat | Preclinical - Pdx | Actionable | In a preclinical study, Tulmimetostat inhibited tumor growth in a bladder cancer patient-derived xenograft (PDX) model harboring a loss of function mutation in ARID1A (PMID: 38833522). | 38833522 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05944562 | Phase I | Tulmimetostat | Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sezary Syndrome | Recruiting | USA | 0 |
| NCT04104776 | Phase Ib/II | Tulmimetostat Irinotecan + Tulmimetostat | A Study of CPI-0209 in Patients With Advanced Solid Tumors | Recruiting | USA | POL | ITA | GBR | FRA | ESP | 1 |
CKB BOOST